Drug Database
FE

felodipine + ramipril (ramipril/felodipine / Tazko / Triapin Mite)

✓ Approved

Sanofi S.A · CACNA1C · 小分子

什么是 felodipine + ramipril?

felodipine + ramipril 是一种小分子,由Sanofi S.A研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名ramipril/felodipine, Tazko, Triapin Mite
公司Sanofi S.A
药物类别小分子
分子靶点CACNA1C, ACE
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

felodipine + ramipril 作用于 2 个分子靶点:

CACNA1Ccalcium voltage-gated channel subunit alpha1 C (CACNL1A1, CACNA1C-IT2)
ACEangiotensin I converting enzyme (DCP1, ACE1)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

felodipine + ramipril 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersHypertension✓ Approved

相关研究文献

PubMedEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences2026-11-15

Development of a non-targeted fingerprint profiling LC-HRMS method combined with chemometric analysis as a new approach for the detection of unexpected impurities.

Schneider Mandy M, Meins Jürgen J, Sandner Viktor V, Schubert-Zsilavecz Manfred M et al.

Valsartan drugs were recalled in 2018 because of the coincidental discovery of unexpected N-nitrosodimethylamine (NDMA). The fact that NDMA was not detected by the established comprehensive quality control methods is mainly due to the targeted approach applied being devoted to the determination of known and expected impurities. This study examines the use of a non-targeted screening approach to monitor the fingerprint profiles of finished products for unexpected impurities. To this end, we developed a profiling method for ramipril tablets using LC-HRMS coupled with SIMCA (soft independent modelling of class analogies) chemometric analysis. Fingerprint profiles were generated using a pentafluorophenyl reversed phase column with a methanol/water gradient coupled to a qTOF mass spectrometer with electrospray ionization in positive and negative mode. By applying chemometric analysis to the untargeted fingerprint profiles, it was possible to distinguish the fingerprint profiles generated from "clean" and spiked ramipril batches at impurity concentrations as low as 10 µg/L demonstrating the methods suitability for trace-level impurity profiling. SIMCA even allowed the identification of the substances responsible for the deviations in the fingerprint profiles. This study shows that untargeted fingerprint profiling coupled with multivariate data analysis is capable of being applied in addition to existing targeted quality control methods as a proactive approach to detect unexpected impurities instead of reactive batch recalls.

PMID 43033898
阅读全文 →
PubMedEuropean journal of case reports in internal medicine2026-11-11

Combined Calcium Channel Blocker And Angiotensin-Converting Enzyme Inhibitor Overdose.

Kahal Fares F, Guérard-Poirier Natasha N, Ji Cheng C, Gursahaney Ashvini A et al.

Combined overdoses of angiotensin-converting enzyme inhibitors and calcium channel blockers are rare but associated with more severe toxicity than either agent alone. A 48-year-old woman presented to the emergency department nine hours after intentionally ingesting 40 tablets of amlodipine (10 mg) and 40 tablets of ramipril (10 mg). On arrival, she was hypotensive and tachycardic. Initial management included fluids, intravenous calcium and insulin bolus followed by high-dose insulin euglycaemic therapy (HIET). Despite escalating vasopressor support, she developed mixed vasoplegic and cardiogenic shock complicated by acute kidney injury, fluid overload, respiratory failure and metabolic acidosis, necessitating intubation and continuous renal replacement therapy. Improvement in haemodynamics was only achieved by day 9. She was transferred from the intensive care unit (ICU) on day 20 with residual weakness from ICU-acquired myopathy and was ultimately discharged after 66 days, with a prolonged hospitalisation attributed to delirium and deconditioning. Severe combined angiotensin-converting enzyme inhibitors (ACEI) and calcium channel blockers (CCB) overdose may cause prolonged, refractory haemodynamic instability requiring extended high-dose insulin euglycaemic therapy (HIET), vasoactive support and fluid administration. Concentrated insulin, dextrose and vasopressor preparations may help mitigate fluid overload. Angiotensin II may be a potential treatment for refractory vasoplegia, although evidence and availability remain limited. Secondary complications can prolong recovery beyond the duration of drug toxicity. This case highlights the need for individualised, multidisciplinary management, early HIET, vasoactive support and fluid-sparing strategies in severe combined ACEI and CCB overdose. Management of severe combined calcium channel blocker and angiotensin-converting enzyme inhibitor overdose may require prolonged resuscitation with high-dose insulin euglycaemic therapy, vasoactive support and fluid administration. The cumulative fluid requirements of these therapies, combined with complications such as acute kidney injury, can contribute to severe fluid overload. The use of concentrated insulin, dextrose and vasopressor preparations may help limit the iatrogenic fluid accumulation.Clinicians should anticipate and proactively manage secondary complications, including acute kidney injury, volume overload, respiratory failure and infection, as these complications may independently prolong recovery beyond the expected duration of drug toxicity.Combined angiotensin-converting enzyme inhibitor and calcium channel blocker overdose lacks established management guidelines and requires individualised, multidisciplinary care based on clinical severity and response to therapy.

PMID 43012017
阅读全文 →
PubMedJournal of family medicine and primary care2026-10-31

Predictors of drug-drug interactions in patients with heart failure.

Tinjić Sabina S, Begić Edin E, Janković Slobodan S, Turalić Amila A et al.

Heart failure (HF) patients are frequently exposed to polypharmacy, placing them at increased risk for drug-drug interactions (DDIs), especially in an outpatient setting where monitoring may be limited. The aim was to assess the prevalence and predictors of clinically relevant DDIs in HF patients and identify patterns associated with higher interaction risk. This cross-sectional observational study included 670 HF patients, treated at a single outpatient cardiology practice. Clinical and pharmacologic data were extracted from medical records. DDIs were identified using the Epocrates interaction checker and classified by severity. Logistic regression and generalized linear models were used to evaluate predictors of avoidable and monitor-required interactions. No contraindicated DDIs were found, but 72.7% of patients had at least one avoidable interaction, and 100% had at least one requiring monitoring. Anticoagulants, mineralocorticoid receptor antagonists, proton pump inhibitor (PPI) use, older age, and HFmrEF and HFpEF phenotypes were significantly associated with increased risk of clinically relevant DDIs. Polypharmacy strongly influenced interaction burden, particularly when ramipril, metformin, atorvastatin, SGLT2 inhibitors, or PPIs were prescribed. Beta-blockers were mildly protective. Clinically significant DDIs are common in HF patients in outpatient care. Risk is highest in older patients, patients with comorbidities requiring multiple pharmacological agents, regimens, and patients with HFmrEF and HFpEF. Structured medication review and attention to high-risk drug combinations are essential to improve safety in HF pharmacotherapy.

PMID 42964872
阅读全文 →
PubMedTranslational and clinical pharmacology2026-10-08

Motility-mediated drug interactions with GLP-1 receptor agonists: labeled evidence and a framework for quantitative assessment.

Chung Jae Yong JY

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely prescribed, and two additional oral products received US approval in 2025 and 2026. All eleven US labels examined describe delayed gastric emptying as potentially affecting the absorption of co-administered oral medications. Since the exenatide program, no study has evaluated a narrow therapeutic index victim across more than one administration schedule; the original warfarin and digoxin studies each used a single schedule. The omission may reflect an interaction paradigm built around enzymes and transporters. Current frameworks do not routinely trigger motility-specific studies because the standard in vitro screening cascade does not address gastric emptying. Total area under the concentration-time curve (AUC) may also fail to characterize rate-dependent effects in some victim drugs. Once a class warning is established, further study may receive less priority, and interactions managed by routine dose adjustment may go unreported. Of eleven US prescribing-information documents screened, six contributed quantitative data showing that the direction of effect is not uniform: thyroxine, atorvastatin and ramipril exposures have all been reported to increase under specific conditions, so a reduction in exposure should not be assumed. The class is also pharmacologically heterogeneous; ICH M12 places absorption-mediated interactions outside its scope, and the European Medicines Agency has adopted a concept paper proposing guidance covering them. I propose an evaluation framework built on biopharmaceutically stratified probe panels, timing- and titration-explicit designs, selective use of prespecified partial AUC endpoints for rate-sensitive victims, and physiologically based pharmacokinetic models qualified against human gastric emptying data.

PMID 42846711
阅读全文 →
PubMedPharmacoepidemiology and drug safety2026-09-28

Brain Penetrant Calcium Channel Blockers Were Not Associated With Reduced Alcohol Consumption: Converging Results From Two Large Independent Cohort Studies Using Electronic Health Records.

Rentsch Christopher T CT, Palzes Vanessa A VA, Shi Mingjian M, Setzer Michael R MR et al.

Alcohol use disorder (AUD) remains a major public health problem, with few effective treatments. L-type calcium channel blockers (LTCCBs) have genetic and preclinical support as potential treatments for AUD. We evaluated whether brain penetrant (BP)-LTCCBs are associated with reduced alcohol consumption in two preregistered observational cohort studies using electronic health records from the US Department of Veterans Affairs (VA) and Kaiser Permanente Northern California (KPNC). New users of BP-LTCCBs (nifedipine or felodipine) were compared with new users of a non-BP-LTCCB (amlodipine) and with unexposed patients from the same clinics, requiring a 180-day washout and ≥ 60 days' supply. Propensity score matching was performed across all exposure contrasts. The primary outcome was change in drinks per week from pre-index to end of follow-up using difference-in-differences (DiD) models, with prespecified subgroup analyses by AUD diagnosis, drinking level, and sex. Across both health systems, BP-LTCCB initiation was not associated with greater reductions in drinks per week than either comparator, with broadly consistent findings across all subgroups; though some subgroups were small and imprecise. In the VA, the DiD comparing BP-LTCCB with non-BP-LTCCB was 0.14 drinks/week (95% CI -0.06, 0.34), and versus unexposed was 0.00 (95% CI -0.18, 0.19). Similar results were observed in KPNC (BP-LTCCB vs. non-BP-LTCCB: 0.31, 95% CI -0.48, 1.11; BP-LTCCB vs. unexposed: 0.16, 95% CI -0.67, 0.99). In two large, preregistered EHR-based cohorts, we found no evidence that BP-LTCCBs were associated with reduced drinking relative to comparators. Despite compelling genetic and preclinical evidence, these findings do not support repurposing BP-LTCCBs for AUD and instead prioritize alternative pharmacologic targets.

PMID 42802293
阅读全文 →
PubMedPharmaceutics2026-09-26

Pharmacokinetic Variability of Direct Oral Anticoagulants and Calcium Channel Blockers: A Comparative Analysis of Exposure Data from Clinical Studies.

Marques Lara L, Vale Nuno N

Background/Objectives: Interindividual pharmacokinetic (PK) variability remains a daunting challenge for effective and safe drug therapy. Despite the widespread use of direct oral anticoagulants (DOACs) and calcium channel blockers (CCBs), a substantial number of adverse drug reactions have been reported for both classes. Herein, this study aimed to assess and analyze the PK variability of DOACs and CCBs across diverse clinical and demographic profiles under both single- and multiple-dose conditions. Methods: A PubMed search identified clinical PK studies reporting maximum plasma concentration (Cmax) and/or area under the concentration-time curve (AUC). The coefficient of variation (CV%) was calculated and used as a measure of PK variability. A CV% < 40% indicated low-to-moderate variability, and a CV% > 40% was defined as high variability. Results: A total of 264 studies were included following systematic screening, and the dataset was further characterized according to population features and clinical context. Among DOACs, edoxaban exhibited the lowest PK variability, whereas dabigatran showed the highest. CCBs demonstrated a broad variability spectrum, ranging from predictable agents (amlodipine and felodipine) to highly variable compounds (nisoldipine, isradipine, nimodipine, diltiazem, and verapamil). Studies evaluating drug-drug interactions, ethnicity, and specific drug-related factors were associated with increased PK variability. Conclusions: These findings suggest that fixed-dose strategies may not be universally appropriate for DOACs and CCBs, particularly in high-risk subgroups where altered exposure may lead to sub- or supratherapeutic concentrations and compromise clinical outcomes. Therefore, clinicians should avoid evaluating individual risk factors in isolation and instead consider the patient's complete profile when selecting and adjusting pharmacotherapy.

PMID 42797278
阅读全文 →

注册免费账户还可查看另外 4259 篇文献

免费注册查看全部文献 →

了解更多felodipine + ramipril